Genmab A/S (GMAB)
33.60
-0.81
(-2.35%)
USD |
NASDAQ |
Sep 04, 16:00
33.56
-0.04
(-0.12%)
After-Hours: 20:00
Genmab Research and Development Expense (Quarterly) : 458.35M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 458.35M |
| March 31, 2026 | 441.63M |
| December 31, 2025 | 525.60M |
| September 30, 2025 | 355.38M |
| June 30, 2025 | 368.90M |
| March 31, 2025 | 359.25M |
| December 31, 2024 | 380.98M |
| September 30, 2024 | 336.16M |
| June 30, 2024 | 361.08M |
| March 31, 2024 | 334.81M |
| December 31, 2023 | 280.90M |
| September 30, 2023 | 304.78M |
| June 30, 2023 | 270.71M |
| March 31, 2023 | 250.97M |
| December 31, 2022 | 224.89M |
| September 30, 2022 | 201.09M |
| June 30, 2022 | 183.40M |
| March 31, 2022 | 173.84M |
| December 31, 2021 | 199.48M |
| September 30, 2021 | 176.57M |
| June 30, 2021 | 149.32M |
| March 31, 2021 | 137.34M |
| December 31, 2020 | 148.32M |
| September 30, 2020 | 113.19M |
| June 30, 2020 | 114.44M |
| Date | Value |
|---|---|
| March 31, 2020 | 105.43M |
| December 31, 2019 | 99.09M |
| September 30, 2019 | 90.56M |
| June 30, 2019 | 84.78M |
| March 31, 2019 | 83.08M |
| December 31, 2018 | 69.80M |
| September 30, 2018 | 53.55M |
| June 30, 2018 | 50.98M |
| March 31, 2018 | 51.58M |
| December 31, 2017 | 43.48M |
| September 30, 2017 | 35.97M |
| June 30, 2017 | 29.85M |
| March 31, 2017 | 24.38M |
| December 31, 2016 | 28.34M |
| September 30, 2016 | 22.58M |
| June 30, 2016 | 28.46M |
| March 31, 2016 | 18.79M |
| December 31, 2015 | 25.94M |
| September 30, 2015 | 17.05M |
| June 30, 2015 | 16.43M |
| March 31, 2015 | 12.91M |
| December 31, 2014 | 22.12M |
| September 30, 2014 | 20.03M |
| June 30, 2014 | 23.67M |
| March 31, 2014 | 24.31M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| AbbVie, Inc. | 2.344B |
| Ascendis Pharma A/S | 85.39M |
| Zealand Pharma A/S | 80.28M |
| Bavarian Nordic A/S | 25.43M |
| Evaxion AS | 2.331M |